ABIVAX
Summary
Abivax SA is a French clinical-stage, publicly traded biotechnology company harnessing the immune system to develop novel treatments against inflammatory diseases, viral diseases and cancer.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 118 M
Avg. Deal Size£ 118 M
All rights reserved. Copyright © 2025 Datasite
